Research
Filter News
Found 148,020 articles
-
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
4/10/2024
Zevra Therapeutics, Inc. today announced that it has entered into a new credit facility provided by leading biotech investors.
-
Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain
4/10/2024
Ginkgo Bioworks today announced the expansion of its strategic partnership with global healthcare leader Novo Nordisk under a framework agreement that initially is contemplated to run over five years.
-
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
4/10/2024
MoonLake Immunotherapeutics today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases.
-
Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002
4/10/2024
Gabather AB (Nasdaq First North Growth Market: GABA) announces that the Company has signed a Collaborative Agreement with the Centre for Neuropsychiatric Schizophrenia Research at the Psychiatric Centre in Glostrup to conduct a so-called clinical phase II study with GT-002 in patients diagnosed with schizophrenia.
-
EpiEndo reports Phase 2A results for lead asset, EP395, in COPD
4/10/2024
EpiEndo Pharmaceuticals announces the successful completion of its Phase 2A clinical trial for EP395 in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).
-
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
4/9/2024
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight® Psychotropic test.
-
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
4/9/2024
Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, and NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for amyotrophic lateral sclerosis (ALS) and other severe neurodegenerative diseases.
-
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
4/9/2024
Genprex, Inc. presented positive preclinical data for Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer.
-
BioMark to Advance Development of Cancer Treatment for Glioblastoma
4/9/2024
BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company") an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today
-
Denovo Biopharma Announces a Major Breakthrough in Treatment‑Resistant Depression with Precision Medicine
4/9/2024
Denovo Biopharma LLC today announced positive results for its biomarker‑guided Phase 2b clinical trial (ENLIGHTEN) designed to assess the efficacy and safety of DB104 (liafensine) in patients with treatment-resistant depression (TRD).
-
Gameto Announces Path Towards a U.S. Phase 3 Trial and Executive and Advisor Appointments
4/9/2024
Gameto today provided an update on its clinical program for their lead asset, Fertilo, their novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSC-IVM) to mature eggs outside of the body, and recent additions to its management team and scientific and clinical advisors.
-
Dovetail Genomics Introduces Novel LinkPrep™ NGS Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
4/9/2024
Dovetail Genomics today announces the debut of its LinkPrep™ NGS technology, showcasing its potential for de novo detection of structural variants and chromatin topology features in cancer.
-
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
4/9/2024
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd . Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.
-
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
4/9/2024
bioAffinity Technologies, Inc. today announced the expansion of its partnership with the American Cancer Society (ACS) to raise funding for ACS’ Lung Quality Improvement (QI) initiative to increase the rate of lung cancer screening.
-
Proprio Announces Strategic Partnership with Biedermann to Revolutionize Surgery Through AI-Powered Guidance
4/9/2024
Proprio today announced a landmark multi-phase partnership with the Biedermann Group, the prominent innovator in next generation spinal implants with Proprio's Paradigm system, which harnesses AI, computer vision, and augmented reality to provide unprecedented real-time visualization and guidance to surgeons in the operating room.
-
NeoImmuneTech's NT-I7 in Combination with Chemotherapy Shows Efficacy in Colorectal Cancer at AACR Meeting
4/9/2024
NeoImmuneTech, Inc. today presented a poster on a pre-clinical study that opens a new field of potential applications for NT-I7 (efineptakin alfa).
-
Sanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i®, Scientist.com’s Supplier Pre-assessment Program
4/9/2024
Sanguine Biosciences Affirms Superior Quality of its Biospecimen Services Using VERIF.i ® , Scientist.com’s Supplier Pre-assessment Program.
-
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
4/9/2024
Nurix Therapeutics, Inc. announced today an extension of the ongoing research program with Sanofi for STAT6 (signal transducer and activator of transcription 6).
-
Vanqua Bio Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating VQ-101, its Small Molecule GCase Activator for GBA-Parkinson’s Disease and Related Disorders
4/9/2024
Vanqua Bio announced that the first patient has been dosed in a first-in-human Phase 1 clinical study evaluating VQ-101 in healthy individuals and patients with various forms of Parkinson’s disease (PD).
-
GammaTile® Marks Milestone: 100th Patient Enrolled in Groundbreaking ROADS Phase 3 Clinical Trial for Newly Diagnosed Metastatic Brain Tumors
4/9/2024
GT Medical Technologies, Inc. today announced it has enrolled the 100th patient in its ROADS clinical study. ROADS, or Radiation One and Done Study, is the randomized control trial (RCT) designed to compare FDA-cleared GammaTile with stereotactic radiotherapy (SRT).